For instance, the prolonged use of MET (hepatocyte growth factor receptor [HGFR]) RTK inhibitors in gastric cancer cell lines in vitro results in loss of DUSP6/MKP-3 expression, which correlates with increased levels of p-ERK [53] while loss of DUSP6/MKP-3 in ovarian cancer has also been linked with cisplatin resistance [54]. This evidence concerns the gene DUSP6 and ovarian carcinoma.